Clinical trials: Oedema
Meniere's Disease, Ménière's Vertigo
Study of Lamotrigine to Treat Ménière's Disease
This double-blinded study evaluates the frequency of vertigo attacks and the quality of life of patients diagnosed with Ménière's disease after being randomly assigned to take a placebo or lamotrigine.
- Conditions
- Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
- Trial name
- NCT02158585
- Testing
- Lamotrigine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dent Neuroscience Research Center
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Hyponatremia, Hypernatremia
Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial
Children who are undergoing surgery need intravenous fluids to prevent dehydration and maintain their electrolyte balance. The current standard of care in these children is to use a fluid which is low in sodium (hypotonic fluid).
- Trial name
- NCT00734214
- Testing
- 0.9% NaCl, 0.45%NaCl
- Where
- Canada
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Acute Kidney Injury, Fluid Overload
Restrictive Versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury
Critically ill patients with acute kidney injury and fluid overload who are frequently treated by fluid removal during dialysis are at an increased risk of complications and death.
- Conditions
- Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications
- Trial name
- RELIEVE-AKI (NCT05306964)
- Testing
- Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Pittsburgh
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Diabetic Macular Edema
Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical coherence tomography (OCT)-guided PRN dosing…
- Trial name
- OZDRY (NCT01892163)
- Testing
- Ozurdex
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Cataract, Retinal Edema
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
- Conditions
- Cataract, Retinal Edema, Inflammation
- Trial name
- QD (NCT01847638)
- Testing
- Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Melissa Toyos
Edematous Fibrosclerotic Panniculopathy (EFP)
A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
- Trial name
- NCT01987986
- Testing
- Collagenase Clostridium Histolyticum
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Oedema, Pulmonary
A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
This study is the first administration of GSK2798745 in humans. This will be a sponsor un-blinded, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745…
- Trial name
- NCT02119260
- Testing
- GSK2798745 solution, GSK2798745 suspension, GSK2798745 capsule
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS)…
- Trial name
- VISTA DME (NCT01363440)
- Testing
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Where
- 51 sites in United States
- Volunteers
- 466 people
- Sponsor
- Regeneron Pharmaceuticals
Sleep Disordered Breathing, Nocturnal Oxygen Desaturation
Determination of the Predictors of Nocturnal Desaturation in Postpartum Women
The primary aim of the study is to evaluate the effect of the method of delivery (vaginal delivery vs. cesarean section) on oxygen saturation in the first postpartum night.
- Conditions
- Sleep Disordered Breathing, Nocturnal Oxygen Desaturation, Upper Airway Edema
- Trial name
- NCT02330055
- Testing
- Forty-five degrees elevated upper body position, non-elevated upper body position, Noninvasive wrist pulse oximeter (WristOx Model 3150)
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Peripheral Edema
Wireless TENS for Peripheral Edema (Lower Limb Swelling)
This study is single center, subject will receive a wireless TENS device. All subjects will be allowed to keep the commercially-available device for use after the study.
- Trial name
- NCT04680533
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Rochester
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.
- Trial name
- NCT02363621
- Testing
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Cirrhosis
A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
OPC-41061 at 7.5 mg/day or placebo will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and the change in body weight from baseline at…
- Trial name
- NCT01050530
- Testing
- OPC-41061
- Where
- 8 sites in Japan
- Volunteers
- 162 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Stroke, Intracranial Hypotension
Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access
Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.
- Conditions
- Stroke, Intracranial Hypotension, Cerebral Edema
- Trial name
- NCT03276494
- Testing
- Intraosseous, Hypertonic saline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the…
- Trial name
- RELEASE-2 (NCT03446781)
- Testing
- EN3835
- Where
- 25 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company